Physician profile
Robert L Boyne
NPI 1134128176
$3,595.00
in general payments reported to CMS, 2019-2025
28 companies · $1,487 in 2025
The $1,487 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $240 · 2021: $241 · 2022: $271 · 2023: $339 · 2024: $758 · 2025: $1,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,583.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,355.40 | 2021-2025 | Qulipta, Ubrelvy |
| Neurocrine Biosciences, INC. | $502.53 | 2023-2025 | Ingrezza, Ongentys |
| Supernus Pharmaceuticals, INC. | $367.80 | 2019-2020 | |
| Pfizer INC. | $221.38 | 2020-2025 | |
| Impel Pharmaceuticals LLC | $149.92 | 2025 | Trudhesa |
| Eisai INC. | $149.52 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $136.03 | 2025 | Ajovy |
| Biogen, INC. | $87.53 | 2025 | Vumerity, Tysabri |
| Grifols USA, LLC | $77.92 | 2025 | Gamunex-C |
| Genentech USA, INC. | $67.83 | 2025 | Ocrevus Zunovo |
| Axsome Therapeutics, INC. | $60.33 | 2025 | Symbravo |
| Amgen INC. | $52.95 | 2019-2025 | Uplizna |
| Averitas Pharma INC. | $51.47 | 2025 | Qutenza |
| Emd Serono, INC. | $43.92 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $42.80 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $37.41 | 2025 | Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $33.97 | 2025 | Hyqvia |
| Otsuka America Pharmaceutical, INC. | $23.36 | 2025 | Nuedexta |
| Sk Life Science, INC. | $19.43 | 2025 | |
| Idorsia Pharmaceuticals US INC | $15.58 | 2024 | Quviviq |
| Lilly USA, LLC | $14.64 | 2025 | Kisunla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.58 | 2019 | |
| Assertio Therapeutics, INC. | $14.57 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.99 | 2020 | |
| Allergan, INC. | $11.94 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.73 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.20 | 2021 | |
| Corium, LLC | $6.27 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Boyne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.